The deal marks the second billion-dollar acquisition by AbbVie in under a week. The company also acquired Immunogen and its ovarian cancer treatment for $10 billion.
Drug pricing experts say CVS' CostVantage program appears designed to pad CVS' own bottom line rather than make drugs cheaper for patients and employers.